JCI vs RAPP · P/E 44, rev $23.60B vs rev $20.0M
Johnson Controls International PLC (JCI) versus Rapport Therapeutics, Inc. Common Stock (RAPP) — a side-by-side from cached financials, not a winner call.
Johnson Controls International PLC (JCI) is a building products & equipment company listed on NYSE.
Rapport Therapeutics, Inc. Common Stock (RAPP) is a biotechnology company listed on US.
Latest reported JCI revenue for 2025-09-30 was $23.60B. Net income was $3.51B. JCI currently screens at market cap $87.62B and trailing P/E 43.9.
Latest reported RAPP revenue for 2026-06-30 was $20.0M. Net income was -$76.5M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. RAPP currently screens at market cap $532.9M.
JCI currently screens at market cap $87.62B and trailing P/E 43.9. RAPP currently screens at market cap $532.9M.
Not investment advice. Open the JCI and RAPP stock pages for the full models.
Not investment advice.